利拉鲁肽联合二甲双胍治疗2型糖尿病的临床疗效及安全性

来源:用户上传      作者:韩昕健 孙秀燕 郝伟 张茹茹

　　[摘要] 目的 探对2型糖尿病患者采用利拉鲁肽+二甲双胍药物完成治疗后获得疗效以及安全性。 方法 选取山东国欣颐养集团枣庄中心医院2018年1月至2020年12月收治的2型糖尿病患者78例作为研究对象;采用随机数表法分为参照组与试验组，每组各39例;分别实施二甲双胍治疗以及利拉鲁肽+二甲双胍治疗;比较两组患者的用药总有效率、HOMA-IR（胰岛素抵抗指数）水平、临床指标[FPG（空腹血糖）、HbAlc（糖化血红蛋白）、2 hPPG（餐后2 h血糖）、BMI（体质量指数）]及不良反应（食欲下降、恶心呕吐、排便次数增加）总发生率。 结果 试验组联合治疗总有效率（94.87%）高于参照组单一治疗总有效率（74.36%）（P<0.05）;治疗前，试验组HOMA-IR水平同参照组比较，差异无统计学意义（P>0.05）;治疗后，同参照组HOMA-IR水平比较，试验组显著降低（P<0.05）;治疗前，两组血糖水平以及体质量指数比较，差异无统计学意义 （P>0.05）;治疗后，同参照组血糖水平以及体质量指数比较，试验组显著降低（P<0.05）。治疗期间两组患者均未表现出日间低血糖或者夜间低血糖等情况。两组以胃肠道不适的出现较为常见;试验组不良反应总发生率（7.68%）同参照组（10.26%）比较，差异无统计学意义（P>0.05）。 结论 利拉鲁肽+二甲双胍药物有效应用，疗效显著，在获得血糖水平降低效果同时，能够将体重减轻，将胰岛素抵抗有效改善，表现出显著应用优势。
　　[关键词] 2型糖尿病;二甲双胍;利拉鲁肽;疗效;安全性
　　[中图分类号] R972.9 [文献标识码] B [文章编号] 1673-9701（2022）13-0122-04
　　[Abstract] Objective To explore the efficacy and safety of liraglutide + metformin after the treatment of type 2 diabetes. Methods A total of 78 patients with type 2 diabetes who were admitted to Zaozhuang Central Hospital，Shandong Guoxin Yiyang Group from January 2018 to December 2020 were selected as the research object. Random number table method was used to divide them into reference group and experimental group. Metformin treatment and liraglutide + metformin treatment were performed respectively， with 39 cases in each group.; The total effective rate， HOMA-IR （insulin resistance index） level， clinical indicators [FPG （fasting blood glucose）， HbAlc （glycated hemoglobin）， 2 hPPG （2 h postprandial blood glucose）， BMI （body mass index）] and the total incidence of adverse reactions （decreased appetite， nausea and vomiting， and increased defecation times） were compared between 2 groups. Results The total effective rate of combined treatment in experimental group （94.87%） was higher than that in reference group （74.36%） （P<0.05）. Before treatment， there was no significant difference in homA-IR level between experimental group and reference group （P>0.05）. After treatment， homA-IR level in experimental group was significantly decreased compared with that in reference group（P<0.05）; Before treatment， there were no significant differences in blood glucose level and body mass index between experimental group and reference group（P>0.05）; After treatment， blood glucose level and body mass index in experimental group were significantly decreased compared with that in reference group（P<0.05）. During the treatment， patients in both groups showed no symptoms of daytime hypoglycemia or nighttime hypoglycemia. Gastrointestinal discomfort was more common in the two groups. There was no significant difference in the total incidence of adverse reactions between the experimental group （7.68%） and the reference group （10.26%） （P>0.05）. Conclusion The effective application of liraglutide + metformin has significant efficacy. It can reduce body weight and effectively improve insulin resistance while achieving the effect of lowering blood glucose level， showing significant advantages.

nlc202206151841

转载注明来源:https://www.xzbu.com/6/view-15433731.htm